MARKET

EYES

EYES

Second Sight Med
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8845
+0.0154
+1.77%
After Hours: 0.8700 -0.0145 -1.64% 17:53 11/15 EST
OPEN
0.9000
PREV CLOSE
0.8691
HIGH
0.9000
LOW
0.8600
VOLUME
120.78K
TURNOVER
--
52 WEEK HIGH
1.400
52 WEEK LOW
0.6351
MARKET CAP
110.20M
P/E (TTM)
-2.1401
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of EYES and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

EYES News

  • Second Sight Medical Products, Inc's (EYES) CEO Will McGuire on Q3 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript.20h ago
  • Second Sight Medical Products (EYES) Reports Q3 Loss, Lags Revenue Estimates
  • Zacks.1d ago
  • Second Sight Medical Q3 EPS $(0.06), Inline
  • Benzinga.1d ago
  • Second Sight Reports Third Quarter 2019 Financial Results
  • Business Wire.1d ago

More

Industry

Medical Equipment, Supplies & Distribution
+1.46%
Healthcare Equipment & Supplies
+1.93%

Hot Stocks

Name
Price
%Change

About EYES

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company intends to develop Orion Visual Cortical Prosthesis which provides useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease or forms of cancer and trauma. Its product, The Argus II Retinal Prosthesis System (The Argus II) provides electrical stimulation of the retina to induce visual perception in blind individuals and helps in treating outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. The Company's Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals.
More

Webull offers Second Sight Medical Products Inc (EYES) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.